FTC Challenges Hospira/Mayne Pharma Deal
On January 18, the Commission announced its challenge to Hospira Inc.’s (“Hospira”) proposed $2 billion acquisition of rival drug manufacturer Mayne Pharma Ltd. (“Mayne”), along with an agreement and order requiring the companies to sell assets used to manufacture and supply five generic injectable pharmaceuticals in order for the transaction to proceed. Absent relief, the FTC charged that the deal would violate U.S. competition laws.
Continue reading " FTC Challenges Hospira/Mayne Pharma Deal " »